MDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum

MDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics
Forum

IRVINE, Calif. and LIEGE, Belgium, Nov. 7, 2013 (GLOBE NEWSWIRE) -- MDxHealth
SA (NYSE Euronext:MDXH), a leading molecular diagnostics company in the field
of personalized cancer treatment, today announced that CEO, Dr. Jan Groen,
will present at the Canaccord Genuity Medical Technology & Diagnostics Forum
in New York on November 14 at 3:30 pm. The presentation will be posted under
the investor tab of the MDxHealth website
(http://mdxhealth.com/investors/shareholder-information).

About MDxHealth^®

MDxHealth is a molecular diagnostics company that develops and commercializes
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company's first commercial product, ConfirmMDx^TM for
Prostate Cancer, has been shown to help distinguish patients who have a
true-negative biopsy from those who may have undetected cancer. MDxHealth
helps to address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary platform
and a strong epigenetic product pipeline focused on the development of
products for prostate, brain and lung cancers. The company is based in Irvine,
California with a European headquarters in Herstal, Belgium. For more
information visit MDxHealth's website at www.mdxhealth.com.

For more information:

Dr. Jan Groen, CEO   Mike Sinclair (Media)  Matt Clawson
MDxHealth            Halsin Partners        Allen & Caron, Inc
US: +1 949 812 6979  UK: +44 20 7318 2955  US: +1 949 474 4300
BE: +32 4 364 20 70 Cell:+44 7968 022075  
info@mdxhealth.com   msinclair@halsin.com   matt@allencaron.com

This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation. This press release does not
constitute an offer or invitation for the sale or purchase of securities or
assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be
offered or sold within the United States without registration under the U.S.
Securities Act of 1933, as amended, or in compliance with an exemption
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service
marks are the property of their respective owners.

To access the PDF version, please click here:
http://hugin.info/137314/R/1741084/584831.pdf
 
Press spacebar to pause and continue. Press esc to stop.